BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx reported Q1 2025 revenues of $0.3 million, a decrease of $6.6 million compared to Q1 2024, primarily due to the out-licensing of APHEXDA. The company successfully reduced its operating expense run rate by over 70% and reaffirmed its cash runway through the second half of 2026. Clinical updates included continued progress in trials for motixafortide in pancreatic cancer and sickle cell disease, with new data to be presented at the upcoming ASCO Annual Meeting.

Analysis

BioLineRx is undergoing a significant strategic transformation, having out-licensed its FDA-approved APHEXDA to Ayrmid Ltd. in Q4 2024, and is now actively evaluating new assets for in-licensing and development in oncology and rare diseases. This pivot is evident in its Q1 2025 financial results: total revenues were $0.3 million, primarily APHEXDA royalties from Ayrmid, a stark decrease from $6.9 million in Q1 2024 which included $5.9 million from a license agreement with Gloria and $0.9 million in APHEXDA product sales. Critically, the company successfully reduced its operating expense run rate by over 70% beginning January 1, 2025, through the APHEXDA program transfer and other reductions, leading to a significantly narrowed operating loss of $2.4 million compared to $4.8 million in Q1 2024. Bolstered by $7.6 million in net non-operating income, largely from fair-value adjustments of warrant liabilities, net income for Q1 2025 reached $5.1 million, compared to $0.7 million in Q1 2024. BioLineRx reaffirmed its cash runway through the second half of 2026, with $26.4 million in cash, cash equivalents, and short-term deposits as of March 31, 2025, further supported by a $10 million financing in January 2025. APHEXDA, under Ayrmid's stewardship, generated $1.4 million in sales in Q1 2025, yielding $0.3 million in royalties for BioLineRx. Clinically, promising updated pilot phase data for motixafortide from the CheMo4METPANC Phase 2b trial in pancreatic cancer, including instances of complete radiological resolution of liver lesions in one patient and a complete pathological response after surgery in another, alongside increased CD8+ T-cell tumor infiltration across all eleven patients, will be presented at the 2025 ASCO Annual Meeting. Full enrollment for this trial, supported by Regeneron and BioLineRx, is planned for 2027. Phase 1 trials for motixafortide in sickle cell disease gene therapy applications are also progressing.

Key Decisions for Investors

• Investors should recognize BioLineRx's transition to a leaner operational model focused on pipeline development, funded by initial APHEXDA royalties, a recent financing, and a cash runway extending through H2 2026.
• The upcoming ASCO presentation on motixafortide in PDAC, particularly the detailed patient responses and immune infiltration data from the pilot phase, represents a significant near-term catalyst to monitor closely.
• Investors should track the company's progress in identifying and in-licensing new oncology and rare disease assets, as this is central to its revised long-term growth strategy beyond the current motixafortide programs.
• Evaluate the investment proposition based on the substantially reduced operating burn and extended financial runway, weighed against the clinical development risks and timelines associated with its motixafortide pipeline and future in-licensed assets.